Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Leiomyosarcoma is a type of cancer that forms in smooth muscle. Researchers want to see if adding ADI-PEG 20 to the usual chemotherapy for leiomyosarcoma works better than chemotherapy alone. The people in this study have leiomyosarcoma that keeps growing despite treatment.
Anaplastic large cell lymphoma (ALCL) is a type of T-cell cancer. This cancer has a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive ALCL.
The purpose of this study is to find the best dose of AZD0120 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
Researchers want to find the best dose of CRD3874-SI to use in people with sarcoma or Merkel cell carcinoma (MCC). The people in this study have sarcoma or MCC that has spread. CRD3874-SI attaches to a type of protein called a STING. This protein encourages immune cells to kill cancer cells, which may slow or stop cancer growth. CRD3874-SI is given intravenously (by vein).
Researchers want to learn if giving ivosidenib with other drugs is safe and works well in people with advanced cholangiocarcinoma. The people in this study have cholangiocarcinoma that has metastasized (spread) and is inoperable (cannot be removed with surgery). Their tumors have a mutation (change) in the IDH1 gene.
The purpose of this study is to find the highest dose of the investigational drug BCA101 that can be given safely alone and in combination with the immunotherapy drug pembrolizumab in patients with advanced lung cancer that cannot be cured with standard treatments. BCA101 is an antibody that targets two proteins involved in cancer growth called EGFR and TGF-beta. By blocking these proteins, BCA101 may interfere with the signals that spur cancer growth. 
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
